Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Clinical Rheumatology Year in Review—2022

Samantha C. Shapiro, MD  |  December 4, 2022

In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR Convergence 2022COVID-19pegloticaseprednisolone

A Shot of Wisdom: Vaccinations in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  December 2, 2022

PHILADELPHIA—The treatment of rheumatic diseases is often a double-edged sword: immunosuppressive regimens can be very effective in reducing disease activity, but the cost of such treatments may be seen in the form of increased risk of infection. At ACR Convergence 2022, the session titled ACR Guidelines for Vaccination in Patients with Rheumatic and Musculoskeletal Diseases…

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsMeeting Reports Tagged with:ACR Convergence 2022COVID-19vaccination

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Walter P. Maksymowych, MB ChB, FACP, FRCP(C)  |  December 1, 2022

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2022ACR Convergence 2022 – PsAPsoriatic Arthritis

Challenges in Psoriatic Arthritis

Samantha C. Shapiro, MD  |  November 29, 2022

PHILADELPHIA—Despite a large and ever-growing number of therapeutic options for our patients with psoriatic disease, it is not uncommon for us come across scenarios in which a patient’s response to therapy does not match our expectations and our shared goals for treatment. We all have those patients—the ones whose joints improve with one drug, but…

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2022ACR Convergence 2022 – PsAPsoriatic Arthritis

Gout Research at a Glance

Lisa Stamp, MBChB, FRACP, PhD  |  November 28, 2022

PHILADELPHIA—Approximately 60 research abstracts on gout were accepted for presentation at ACR Convergence 2022, including two plenary abstract presentations. It is exciting to see a wealth of research on gout being undertaken worldwide. Here, we highlight important points from seven of these studies. 1. Abstract 1810: Frequency and Patterns of Opioid Use in the Management…

Filed under:ConditionsGout and Crystalline ArthritisMeeting ReportsResearch Rheum Tagged with:ACR Convergence 2022ACR Convergence 2022 – Gout

Options for Refractory Gout, ILD & More

Ruth Jessen Hickman, MD  |  November 18, 2022

PHILADELPHIA—At the first Plenary Session of ACR Convergence 2022, on Saturday, Nov. 12, speakers shared key research findings on the efficacy and safety of methotrexate as a co-therapy with pegloticase in refractory gout, the effectiveness of rituximab and cyclophosphamide in connective tissue disease associated-interstitial lung disease and the value of remote education for primary care…

Filed under:ConditionsGout and Crystalline ArthritisOther Rheumatic ConditionsSystemic Sclerosis Tagged with:ACR Convergence 2022ACR Convergence 2022 – Gout

ACR Scores Wins for Rheumatology Community at AMA House of Delegates Interim Meeting

From the College  |  November 17, 2022

Key successes for the rheumatology community secured by the ACR’s delegation include passage of the ACR’s resolution addressing pharmacy benefit administrators, advances in policies to protect rheumatologists and patients in the post-Dobbs landscape and retention of the rheumatology’s representation in the AMA House of Delegates.

Filed under:Legislation & Advocacy Tagged with:ACR advocacyAMA House of Delegates (HOD)third-party pharmacy benefit administrators

Bangalore House Call: A Patient’s Story

Charles Radis, DO  |  November 9, 2022

On a highway traversed by cement trucks and Beetle-Bug auto-rickshaws we travel north from Bangalore, India, for a house call. It is 2007, and the city leaves us grudgingly. Between fields of loose chocolate soil and sprigs of beans poking skyward, the skeletons of homes and businesses rise; armies of workers lay brick from wooden…

Filed under:ConditionsPatient PerspectiveRheumatoid Arthritis Tagged with:case reportHistory

TNF Inhibitors Associated with Neurological Adverse Events

Michele B. Kaufman, PharmD, BCGP  |  November 7, 2022

A study examined the association between TNF inhibitors and neurological demyelinating adverse events in patients with rheumatoid arthritis and spondyloarthritis using cohort data from five Nordic countries. Researchers showed that patients with SpA were more likely to experience adverse events than patients with RA.

Filed under:ConditionsDrug Updates Tagged with:adverse eventsbrainEULARneurological demyelinating adverse eventsTNF inhibitorstumor necrosis factor (TNF) inhibitors

Speak Out Rheum: To Prescribe Is Humane (Unless You’re In Texas)

Raymond Scalettar, MD, DSc  |  November 7, 2022

You are a rheumatologist in Texas. You are very well trained. Your mentors included some of the leaders in rheumatology, and you are respected by your colleagues and your patients. You know the devastation of untreated rheumatoid arthritis and lupus. A young woman with recent onset of systemic lupus erythematosus is your new patient. You…

Filed under:EthicsLegal UpdatesOpinionProfessional TopicsSpeak Out Rheum Tagged with:abortionMethotrexatepregnancySpeak Out Rheumatology

  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 107
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences